{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969341",
  "id": "02969341",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250715",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06lt23fwr9kjz3.pdf",
  "summary": "**Clinical Trial Update Announcement (MagSense HER2 Breast Cancer Program)**  \n- **FDA meeting outcome**: No issues identified; Phase 2 trial plans remain on track.  \n- **IND application timeline**: Submission expected Q3 2025.  \n- **Manufacturing update**: MagSense HER2 imaging agent production to be fast-tracked, completion targeted for Q3 2025.  \n\n*No material capital markets or trading-specific information identified.*",
  "usage": {
    "prompt_tokens": 1508,
    "completion_tokens": 92,
    "total_tokens": 1600,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T23:32:14.791165"
}